Business Insider AustraliaNovartis lung drug not inferior to GSK’s Seretide, study showsReutersZURICH (Reuters) – Patients taking Novartis’ inhaled medicine Onbrez Breezhaler for chronic lung disease had benefits similar to those taking GlaxoSmithKline’s Seretide, the Swiss drugmaker said on Friday, citing a late stage study. Also known as QVA149, …Novartis’ INSTEAD study for Onbrez(R) Breezhaler(R) in patients with moderate …MarketWatchNovartis INSTEAD Switch Study For Onbrez Breezhaler Meets Primary ObjectiveRTT NewsNovartis lung drug not inferior to GSK’s SeretideUpdated NewsNASDAQall 5 news articles …Read Full Story
Novartis lung drug not inferior to GSK's Seretide, study shows - Reuters
Real Estate of Cebu
